Protagenic Therapeutics (PTIX) Faces Nasdaq Delisting Over Compliance Issues
Key Takeaways: Protagenic Therapeutics (PTIX) faces potential delisting from Nasdaq due to non-compliance with listing requirements. The company operates
www.gurufocus.comProtagenic Therapeutics (PTIX) has been in the news recently, with coverage focused on its PT00114 program, potential Nasdaq delisting issues in late 2025, and ongoing clinical milestones through 2026. Below is a concise roundup with key points and caveats.
Latest headlines and themes
- PT00114 developments: Multiple-dose Phase 1 safety data showed tolerability across dose ranges, fueling plans to move to Phase 2 in 2026 for depression, anxiety, and related mood/stress disorders. This remains a central driver of investor interest.[1][3]
- Nasdaq listing status: In late 2025, PTIX faced potential delisting due to non-compliance with listing requirements (stockholders’ equity minimum and timely reporting). The company indicated it would pursue a hearing and corrective actions.[2]
- 2026 milestones and restructuring: Reports indicate the company cut debt and streamlined liabilities, reinforcing PT00114 as the primary clinical priority and aiming for Phase 2 enrollment in 2026.[3]
Context and cautions
- Stock performance and volatility: PTIX has experienced significant stock price fluctuations and periods of low pricing in prior years, common for small-cap biotech names with early-stage clinical programs.[4][6]
- Competitive and regulatory landscape: Biotech stocks tied to CNS and mood-disorder therapies can be sensitive to trial readouts, regulatory milestones, and financing developments; PTIX’s trajectory depends on Phase 2 results and Nasdaq-related actions.[1][2]
What this means for you
- If you’re tracking PTIX for investment or research purposes, monitor upcoming Phase 2 enrollment timelines and any Nasdaq hearing outcomes, as these will influence valuation and liquidity. The 2026 Phase 2 initiation is a key catalyst to watch.[3][1]
- Be aware of potential volatility around delisting news and quarterly/annual report filings, as these factors can impact share price and trading activity in the near term.[2]
Would you like me to pull the latest official press releases or build a brief timeline of PTIX milestones with dates for quick reference? I can also create a short chart showing reported milestones and expected Phase 2 timelines if you want.